Plasma Proteome-Based Test for First-Line Treatment Selection in Metastatic Non-Small Cell Lung Cancer.
Publication/Presentation Date
3-1-2024
Abstract
PURPOSE: Current guidelines for the management of metastatic non-small cell lung cancer (NSCLC) without driver mutations recommend checkpoint immunotherapy with PD-1/PD-L1 inhibitors, either alone or in combination with chemotherapy. This approach fails to account for individual patient variability and host immune factors and often results in less-than-ideal outcomes. To address the limitations of the current guidelines, we developed and subsequently blindly validated a machine learning algorithm using pretreatment plasma proteomic profiles for personalized treatment decisions.
PATIENTS AND METHODS: We conducted a multicenter observational trial (ClinicalTrials.gov identifier: NCT04056247) of patients undergoing PD-1/PD-L1 inhibitor-based therapy (n = 540) and an additional patient cohort receiving chemotherapy (n = 85) who consented to pretreatment plasma and clinical data collection. Plasma proteome profiling was performed using SomaScan Assay v4.1.
RESULTS: Our test demonstrates a strong association between model output and clinical benefit (CB) from PD-1/PD-L1 inhibitor-based treatments, evidenced by high concordance between predicted and observed CB (
CONCLUSION: Plasma proteome-based testing of individual patients, in combination with standard PD-L1 testing, distinguishes patient subsets with distinct differences in outcomes from PD-1/PD-L1 inhibitor-based therapies. These data suggest that this approach can improve the precision of first-line treatment for metastatic NSCLC.
Volume
8
First Page
2300555
Last Page
2300555
ISSN
2473-4284
Published In/Presented At
Christopoulos, P., Harel, M., McGregor, K., Brody, Y., Puzanov, I., Bar, J., Elon, Y., Sela, I., Yellin, B., Lahav, C., Raveh, S., Reiner-Benaim, A., Reinmuth, N., Nechushtan, H., Farrugia, D., Bustinza-Linares, E., Lou, Y., Leibowitz, R., Kamer, I., Zer Kuch, A., … Gandara, D. R. (2024). Plasma Proteome-Based Test for First-Line Treatment Selection in Metastatic Non-Small Cell Lung Cancer. JCO precision oncology, 8, e2300555. https://doi.org/10.1200/PO.23.00555
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
38513170
Department(s)
Administration and Leadership
Document Type
Article